IPG Photonics (IPGP) AI Stock Analysis
IPG Photonics
(BMV:IPGP)
No summary available
IPG Photonics (IPGP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 3.17B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 77.5
- Beta (1Y)
- 0.07
- Revenue Growth
- 3.01%
- EPS Growth
- 42.26%
- Country
- Mexico
- Employees
- 4,840
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Semiconductors
IPG Photonics Business Overview & Revenue Model
Company Description
Established in 1990 and headquartered in Oxford, Massachusetts, IPG Photonics Corporation is a leading global developer and manufacturer of high-performance fiber, diode, and hybrid fiber-solid state lasers, along with fiber amplifiers. These advance...
IPG Photonics Earnings Call Summary
The call was strongly positive overall. Revenue increased 15% year over year for the fourth consecutive quarter of double-digit growth, Advanced Solutions grew 33%, semiconductor revenue more than doubled, bookings remained solid, margins exceeded guidance, and the company reported a strong cash position with no debt. The main challenges were moderation in China battery capacity additions, a year-over-year decline in European revenue, lumpy defense timing, limited cutting growth, inflationary pressures, and the absence of tariff-refund benefits in fourth-quarter guidance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter of 26, IPG expects revenue of $265 million to $295 million, adjusted gross margin to be between 37% to 40%, adjusted operating expenses in the range of $91 million to $94 million, adjusted earnings per diluted share in the range of $0.30 to $0.60 with approximately 43 million diluted common shares outstanding, and adjusted EBITDA between $33 million and $50 million; this guidance does not assume any contribution from the acquisition of Lumibird Medical. The company expects operating expenses to increase modestly going forward, expects CapEx excluding the German investment to be at about 5% of revenue going forward, sees medical doubling over the next 2 to 3 years, expects Lumibird Medical to be accretive in 2027, in that first year, and expects to reach a 39% range for gross margin with several 100 basis points of gain and more meaningful gains in gross margin in 2027.
IPG Photonics Risk Analysis
IPG Photonics disclosed 37 risk factors in its most recent earnings report. IPG Photonics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskIPG Photonics Peers Comparison
Overall Rating
LASR60Neutral
AXTI57Neutral
VECO52Neutral
AEVA46Neutral
POET39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| 60Neutral | $2.06B | -146.45 | -3.80% | ― | 43.24% | 74.67% | |
| 57Neutral | $3.16B | 109.58 | 5.40% | ― | 89.14% | ― | |
| 52Neutral | $2.28B | 97.60 | 2.62% | ― | -2.52% | -64.30% | |
| 46Neutral | $599.47M | -44.70 | -210.69% | ― | 56.22% | 93.61% | |
| 39Underperform | $829.81M | -7.13 | -19.59% | ― | 266.06% | 19.55% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:IPGP | Ipg Photonics | 1350.01 | -103.99 | -7.15% | |
| AXTI | AXT Inc | 51.33 | 42.23 | 464.07% | |
| VECO | Veeco Instruments Inc | 37.39 | 7.94 | 26.96% | |
| POET | Poet Technologies Inc. | 5.09 | -0.95 | -15.66% | |
| LASR | Nlight | 36.51 | 5.01 | 15.90% | |
| AEVA | Aeva Technologies, Inc. | 8.94 | -4.84 | -35.12% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.